Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines

References

• Foster T. Colonization and infection of the human host by staphylococci: adhesion, survival and immune evasion. Vet. Dermatol.20, 456–470 (2009).
   PubMed Web of Science ®Google Scholar
• Kale-Pradhan P, Johnson LB. Treatment and recurrence management of staphylococcal infections: community-acquired MRSA. Expert Rev. Anti Infect. Ther.6(6), 909–915 (2008).
   PubMed Web of Science ®Google Scholar
• David A, Risitano DC, Mazzeo G, Sinardi L, Venuti FS, Sinardi AU. Central venous catheters and infections. Minerva Anestesiol.71(9), 561–564 (2005).
   PubMedGoogle Scholar
• David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev.23(3), 616–687 (2010).
   PubMed Web of Science ®Google Scholar
• Plata K, Rosato AE, Wegrzyn G. Staphylococcus aureus as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity. Acta Biochim. Pol.56(4), 597–612 (2009).
   PubMed Web of Science ®Google Scholar
• van Belkum A. Staphylococcal colonization and infection: homeostasis versus disbalance of human (innate) immunity and bacterial virulence. Curr. Opin. Infect. Dis.19(4), 339–344 (2006).
   PubMed Web of Science ®Google Scholar
• Nanra JS, Timofeyeva Y, Buitrago SM et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine27(25–26), 3276–3280 (2009).
   PubMed Web of Science ®Google Scholar
• Nübel U, Dordel J, Kurt K et al. A timescale for evolution, population expansion, and spatial spread of an emerging clone of methicillin-resistant Staphylococcus aureus. PLoS Pathog.6(4), e1000855 (2010).
   Web of Science ®Google Scholar
• Harro JM, Peters BM, O’May GA et al. Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunol. Med. Microbiol.59(3), 306–323 (2010).
   PubMed Web of Science ®Google Scholar
• von Eiff C. Staphylococcus aureus small colony variants: a challenge to microbiologists and clinicians. Int. J. Antimicrob. Agents31(6), 507–510 (2008).
   PubMed Web of Science ®Google Scholar
• Schaffer AC, Lee JC. Vaccination and passive immunisation against Staphylococcus aureus. Int. J. Antimicrob. Agents32(Suppl. 1), 71–78 (2008).
   PubMed Web of Science ®Google Scholar
• Clarke SR, Brummell KJ, Horsburgh MJ et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis.193(8), 1098–1108 (2006).
   PubMed Web of Science ®Google Scholar
• Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA99(10), 6573–6578 (2002).
   PubMed Web of Science ®Google Scholar
• Sellman BR, Howell AP, Kelly-Boyd C, Baker SM. Identification of immunogenic and serum binding proteins of Staphylococcus epidermidis. Infect. Immun.73(10), 6591–6600 (2005).
   PubMed Web of Science ®Google Scholar
• Glowalla E, Tosetti B, Kronke M, Krut O. Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect. Immun.77(7), 2719–2729 (2009).
   PubMed Web of Science ®Google Scholar
• Solis N, Larsen M. Improved accuracy of cell surface shaving proteomics in Staphylococcus aureus using a false-positive control. Proteomics10(10), 2037–2049 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, Schneewind O. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog.6(8), pii: e1001036 (2010).
   Google Scholar
• Kim HK, Cheng AG, Kim H-Y, Missiakas DM, Schneewind O. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J. Exp. Med.207(9), 1863–1870 (2010).
   PubMed Web of Science ®Google Scholar
• Rivas JM, Speziale P, Patti JM, Hook M. MSCRAMM-targeted vaccines and immunotherapy for staphylococcal infection. Curr. Opin. Drug Discov. Devel.7(2), 223–227 (2004).
   PubMedGoogle Scholar
• Schaffer AC, Solinga RM, Cocchiaro J et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun.74(4), 2145–2153 (2006).
   PubMed Web of Science ®Google Scholar
• Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl Acad. Sci. USA103(45), 16942–16947 (2006).
   PubMed Web of Science ®Google Scholar
• Somerville G, Proctor R. At the crossroads of bacterial metabolism and virulence factor synthesis in staphylococci. Microbiol. Mol. Biol. Rev.73(2), 233–248 (2009).
   PubMed Web of Science ®Google Scholar
• Tuchscherr LPN, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect. Immun.76(12), 5738–5744 (2008).
   PubMed Web of Science ®Google Scholar
• Leijh PC, van den Barselaar MT et al. Kinetics of phagocytosis of Staphylococcus aureus and Escherichia coli by human granulocytes. Immunology37(2), 453–465 (1979).
   PubMed Web of Science ®Google Scholar
• Leijh PC, van den Barselaar MT, Daha MR, van Furth R. Participation of immunoglobulins and complement components in the intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes. Infect. Immun.33(3), 714–724 (1981).
   PubMed Web of Science ®Google Scholar
• Dryla A, Prustomersky S, Gelbmann D et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab. Immunol.12(3), 387–398 (2005).
   PubMedGoogle Scholar
• Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N. Engl. J. Med.325(2), 110–117 (1991).
   PubMed Web of Science ®Google Scholar
• Liese JG, Wintergerst U, Tympner KD, Belohradsky BH. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am. J. Dis. Child.146(3), 335–339 (1992).
   PubMedGoogle Scholar
• Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin. Infect. Dis.36(3), 281–285 (2003).
   PubMed Web of Science ®Google Scholar
• Brown M, Kowalski R, Zorman J et al. Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin. Vaccine Immunol.16(8), 1095–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Burnie JP, Matthews RC, Carter T et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun.68(6), 3200–3209 (2000).
   PubMed Web of Science ®Google Scholar
• Garmory HS, Titball RW. ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect. Immun.72(12), 6757–6763 (2004).
   PubMed Web of Science ®Google Scholar
• Veldkamp KE, Van Kessel KP, Verhoef J, Van Strijp JA. Staphylococcal culture supernates stimulate human phagocytes. Inflammation21(5), 541–551 (1997).
   PubMed Web of Science ®Google Scholar
• von Kockritz-Blickwede M, Rohde M, Oehmcke S et al. Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model. Am. J. Pathol.173(6), 1657–1668 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barca E, Carratala J, Mykietiuk A, Fernandez-Sevilla A, Gudiol F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur. J. Clin. Microbiol. Infect. Dis.20(2), 117–119 (2001).
   PubMed Web of Science ®Google Scholar
• Liese JG, Jendrossek V, Jansson A et al. Chronic granulomatous disease in adults. Lancet347(8996), 220–223 (1996).
   PubMed Web of Science ®Google Scholar
• Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol. Res.34(3), 229–242 (2006).
   PubMed Web of Science ®Google Scholar
• McLoughlin RM, Solinga RM, Rich J et al. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc. Natl Acad. Sci. USA103(27), 10408–10413 (2006).
   PubMed Web of Science ®Google Scholar
• McLoughlin RM, Lee JC, Kasper DL, Tzianabos AO. IFN-γ regulated chemokine production determines the outcome of Staphylococcus aureus infection. J. Immunol.181(2), 1323–1332 (2008).
   PubMed Web of Science ®Google Scholar
• Lin L, Ibrahim AS, Xu X et al. Th1–Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog.5(12), e1000703 (2009).
   PubMed Web of Science ®Google Scholar
• Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y, Nakane A. Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect. Immun.78(10), 4234–4242 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, Missiakas DM. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J.23(10), 3393–3404 (2009).
   PubMed Web of Science ®Google Scholar
• Plotkin S. Vaccines: the fourth Century. Clin. Vaccine Immunol.16(12), 1709–1719 (2009).
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Bubeck Wardenburg J, Gardner DJ et al. Targeting of α-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis.202(7), 1050–1058 (2010).
   PubMed Web of Science ®Google Scholar
• Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med.205(2), 287–294 (2008).
   PubMed Web of Science ®Google Scholar
• Brown EL, Dumitrescu O, Thomas D et al. The Panton–Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect.15(2), 156–164 (2009).
   Web of Science ®Google Scholar
• Hermos CR, Yoong P, Pier GB. High levels of antibody to Panton–Valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin. Infect. Dis.51(10), 1138–1146 (2010).
   PubMed Web of Science ®Google Scholar
• Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX(™), a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to Phase III clinical trials. Vaccine22(7), 880–887 (2004).
   PubMed Web of Science ®Google Scholar
• Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J. Infect. Dis.187(9), 1452–1459 (2003).
   PubMed Web of Science ®Google Scholar
• Klevens R, Morrison M, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA298(15), 1763–1717 (2007).
   PubMed Web of Science ®Google Scholar
• Lucero CA, Hageman J, Zell ER et al. Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine27(37), 5061–5068 (2009).
   PubMed Web of Science ®Google Scholar
• Ena J, Boelaert JR, Boyken LD, Van Landuyt HW, Godard CA, Herwaldt LA. Epidemiology of Staphylococcus aureus infections in patients on hemodialysis. Infect. Control Hosp. Epidemiol.15(2), 78–81 (1994).
   PubMed Web of Science ®Google Scholar
• Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev.10(3), 505–520 (1997).
   PubMed Web of Science ®Google Scholar
• Leung AD, Schiltz AM, Hall CF, Liu AH. Severe atopic dermatitis is associated with a high burden of environmental Staphylococcus aureus. Clin. Exp. Allergy38(5), 789–793 (2008).
   PubMed Web of Science ®Google Scholar
• Piraino B, Perlmutter JA, Holley JL, Bernardini J. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit. Dial. Int.13(Suppl. 2), S332–S334 (1993).
   Google Scholar
• von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N. Engl. J. Med.344(1), 11–16 (2001).
   PubMed Web of Science ®Google Scholar
• Wertheim HFL, Vos MC, Ott A et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet364(9435), 703–705 (2004).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Auranen K, Nohynek H, Dagan R, Mäkelä H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev. Vaccines5(5), 651–667 (2006).
   PubMed Web of Science ®Google Scholar
• Galambos L, Sewell J. Networks of Innovation. Cambridge University Press, Cambridge, UK (1995).
   Google Scholar
• Fleming A. Recent advances in vaccine therapy. Br. Med. J.15, 100–104 (1939).
   Google Scholar
• Schwander R. Therapeutic experience with staphypan Berna. Schweiz. Med. Wochenschr.84(2), 37–38 (1954).
   PubMedGoogle Scholar
• Andersson M, Bagby J, Dyrehag L, Gottfries C. Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. Eur. J. Pain2, 133–142 (1998).
   PubMed Web of Science ®Google Scholar
• Crossley K, Archer G, Jefferson K, Fowler V. Staphylococci in Human Disease. Wiley-Blackwell, Hoboken, NJ, USA (2009).
   Google Scholar
• Murphy E, Lin S, Nunez L et al. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum. Vaccin.7, 51–59 (2011).
   PubMed Web of Science ®Google Scholar
• Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun.64(5), 1659–1665 (1996).
   PubMed Web of Science ®Google Scholar
• Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun.65(10), 4146–4151 (1997).
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med.346(7), 491–496 (2002).
   PubMed Web of Science ®Google Scholar
• Cook J, Hepler R, Pancari G et al. Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection. Hum. Vaccin.5(4), 254–263 (2009).
   PubMed Web of Science ®Google Scholar
• Han HR, Pak S, Guidry A. Prevalence of capsular polysaccharide (CP) types of Staphylococcus aureus isolated from bovine mastitic milk and protection of S. aureus infection in mice with CP vaccine. J. Vet. Med. Sci.62(12), 1331–1333 (2000).
   PubMed Web of Science ®Google Scholar
• Josefsson E, Hartford O, O’Brien L, Patti J, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis.184(12), 1572–1580 (2001).
   PubMed Web of Science ®Google Scholar
• Josefsson E, Higgins J, Foster TJ, Tarkowski A. Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. PLoS ONE3(5), e2206 (2008).
   PubMed Web of Science ®Google Scholar
• Vernachio J, Bayer AS, Le T et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob. Agents Chemother.47(11), 3400–3406 (2003).
   PubMed Web of Science ®Google Scholar
• Meinke A, Henics T, Nagy E. Bacterial genomes pave the way to novel vaccines. Curr. Opin. Microbiol.7(3), 314–320 (2004).
   PubMed Web of Science ®Google Scholar
• Meinke A, Henics T, Hanner M, Minh D, Nagy E. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. Vaccine23, 2035–2041 (2005).
   PubMed Web of Science ®Google Scholar
• von Gaban A. Intercell Scientific Review. Presented at: Rodman and Renshaw Conference. Paris, France, 9 September 2009.
   Google Scholar
• Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun.74(4), 2215–2223 (2006).
   PubMed Web of Science ®Google Scholar
• Moustafa M, Buerkert J, Sobeih T et al. The immunogenicity and safety of a novel Staphylococcus aureus vaccine (V710) in adults with end-stage renal disease receiving hemodialysis – a Phase IIA study. Presented at: National Kidney Foundation 2011 Spring Clinical Meeting. Las Vegas, NV, USA, April 26–30 2011.
   Google Scholar
• Richmond P, Nissen M, Marshall H et al. A randomised, placebo controlled Phase 1 first-in-human study of a novel 3-antigen Staphylococcus aureus vaccine in healthy adults. Presented at: 21st Annual Meeting of the European Society of Clinical Microbiology and Infectious diseases. Milan Italy, 7–10 May 2011 (LB2769).
   Google Scholar
• Antonen JA, Pyhälä R, Hannula PM et al. Influenza vaccination of dialysis patients: cross-reactivity of induced haemagglutination-inhibiting antibodies to H3N2 subtype antigenic variants is comparable with the response of naturally infected young healthy adults. Nephrol. Dial. Transplant.18(4), 777–781 (2003).
   PubMed Web of Science ®Google Scholar
• Brydak LB, Roszkowska-Blaim M, Machala M, Leszczynska B, Sieniawska M. Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases. Vaccine18(28), 3280–3286 (2000).
   PubMed Web of Science ®Google Scholar
• Cappel R, Van Beers D, Liesnard C, Dratwa M. Impaired humoral and cell-mediated immune responses in dialyzed patients after influenza vaccination. Nephron33(1), 21–25 (1983).
   PubMed Web of Science ®Google Scholar
• Davis JP. Experience with hepatitis A and B vaccines. Am. J. Med.118(Suppl. 10A), 7S–15S (2005).
   PubMed Web of Science ®Google Scholar
• Fleischmann EH, Kruppenbacher J, Bock HL, Weber M. Active immunization against hepatitis A in dialysis patients. Nephrol. Dial. Transplant.17(10), 1825–1828 (2002).
   PubMed Web of Science ®Google Scholar
• Kazancioglu R, Sever MS, Yuksel-Onel D et al. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine. Clin. Transplant.14(1), 61–65 (2000).
   PubMed Web of Science ®Google Scholar
• Kramer J, Stachowski J, Barth C et al. Genetic regulation of the impaired immune response to hepatitis-B vaccine associated with low TCR density in end stage renal disease patients: contribution of complement C4 and factor B alleles. Immunol. Lett.59(1), 13–19 (1997).
   PubMed Web of Science ®Google Scholar
• Kruger S, Seyfarth M, Sack K, Kreft B. Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphtheria vaccination. Vaccine17(9–10), 1145–1150 (1999).
   PubMed Web of Science ®Google Scholar
• Liu Y-L, Kao M-T, Huang C-C. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine23(30), 3957–3960 (2005).
   PubMed Web of Science ®Google Scholar
• Sezer S, Ozdemir FN, Guz G et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant. Proc.32(3), 607–608 (2000).
   PubMed Web of Science ®Google Scholar
• Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatol. Online J.9(2), 1 (2003).
   PubMedGoogle Scholar
• Breuer K, Haussler S, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br. J. Dermatol.147(1), 55–61 (2002).
   PubMed Web of Science ®Google Scholar
• Gilani SJK, Gonzalez M, Hussain I, Finlay AY, Patel GK. Staphylococcus aureus re-colonization in atopic dermatitis: beyond the skin. Clin. Exp. Dermatol.30(1), 10–13 (2005).
   PubMed Web of Science ®Google Scholar
• Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med.357(4), 380–390 (2007).
   PubMed Web of Science ®Google Scholar
• Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr. Infect. Dis. J.20(9), 860–863 (2001).
   PubMed Web of Science ®Google Scholar
• Hota B, Ellenbogen C, Hayden MK, Aroutcheva A, Rice TW, Weinstein RA. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission? Arch. Intern. Med.167(10), 1026–1033 (2007). Erratum in: Arch. Intern. Med.167(14), 1455 (2007).
   PubMedGoogle Scholar
• Miller LG, Kaplan SL. Staphylococcus aureus: a community pathogen. Infect. Dis. Clin. N. Am.23(1), 35–52 (2009).
   PubMed Web of Science ®Google Scholar
• Graves EJ, Kozak LJ. National hospital discharge survey: annual summary, 1996. Vital. Health Stat.13(140), I–IV (1999).
   Google Scholar
• Noskin G, Rubin R, Schentag J et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998–2003). Clin. Infect. Dis.45(9), 1132–1140 (2007).
   PubMed Web of Science ®Google Scholar
• Petti CA, Sanders LL, Trivette SL, Briggs J, Sexton DJ. Postoperative bacteremia secondary to surgical site infection. Clin. Infect. Dis.34(3), 305–308 (2002).
   PubMed Web of Science ®Google Scholar
• Hempel K, Pané-Farré J, Otto A, Sievers S, Hecker M, Becher D. Quantitative cell surface proteome profiling for SigB-dependent protein expression in the human pathogen Staphylococcus aureus via biotinylation approach. J. Proteome Res.9(3), 1579–1590 (2004).
   Google Scholar
• Schmaler M, Jann NJ, Götz F, Landmann R. Staphylococcal lipoproteins and their role in bacterial survival in mice. Int. J. Med. Microbiol.300(2–3), 155–160 (2010).
   PubMed Web of Science ®Google Scholar
• Clarke SR, Foster SJ. Surface adhesins of Staphylococcus aureus. Adv. Microb. Physiol.51, 187–224 (2006).
   PubMed Web of Science ®Google Scholar